Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) shot up 5.7% during trading on Wednesday . The company traded as high as $11.99 and last traded at $12.14. 509,094 shares were traded during trading, a decline of 83% from the average session volume of 3,041,534 shares. The stock had previously closed at $11.48.
Analyst Ratings Changes
A number of brokerages recently commented on NTLA. Guggenheim dropped their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Chardan Capital restated a "buy" rating and set a $68.00 price target on shares of Intellia Therapeutics in a research note on Friday, May 9th. Citigroup dropped their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Wedbush reissued a "neutral" rating and issued a $7.00 price target on shares of Intellia Therapeutics in a report on Monday, June 16th. Finally, Wolfe Research raised shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target for the company in a report on Monday, April 21st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $33.37.
View Our Latest Analysis on NTLA
Intellia Therapeutics Trading Down 1.1%
The business's 50 day moving average price is $9.31 and its two-hundred day moving average price is $9.35. The stock has a market cap of $1.23 billion, a P/E ratio of -2.26 and a beta of 2.21.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The firm had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the previous year, the firm posted ($1.12) EPS. The company's revenue for the quarter was down 42.6% compared to the same quarter last year. As a group, analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.
Institutional Investors Weigh In On Intellia Therapeutics
Several hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System lifted its position in Intellia Therapeutics by 4.1% during the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock valued at $1,057,000 after purchasing an additional 3,596 shares during the period. Raymond James Financial Inc. bought a new position in Intellia Therapeutics during the fourth quarter valued at approximately $4,793,000. Baker BROS. Advisors LP bought a new position in Intellia Therapeutics during the fourth quarter valued at approximately $7,510,000. XTX Topco Ltd increased its holdings in Intellia Therapeutics by 194.6% during the fourth quarter. XTX Topco Ltd now owns 43,908 shares of the company's stock valued at $512,000 after buying an additional 29,006 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Intellia Therapeutics by 12.1% during the fourth quarter. Deutsche Bank AG now owns 252,501 shares of the company's stock valued at $2,944,000 after buying an additional 27,282 shares during the last quarter. Institutional investors own 88.77% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
